Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Advantech Europe
KOREA E & EX

Expandable Arterial Stent Helps Treat Iliac Stenosis

By HospiMedica International staff writers
Posted on 04 Jun 2014
Image: The Visi-Pro balloon-expandable stent system (Photo courtesy of Covidien).
Image: The Visi-Pro balloon-expandable stent system (Photo courtesy of Covidien).
A balloon-expandable stent system helps patients regain blood flow by treating lesions of the common and external iliac arteries.

The Visi-Pro balloon-expandable stent system is intended to improve and maintain artery luminal diameter in occlusions or lesions at high risk for abrupt closure following percutaneous transluminal angioplasty (PTA), or in lesions believed to be at high risk of stenosis following PTA in the common and external iliac, subbclavian, and renal arteries. The stent is also indicated for use as a palliative treatment of malignant neoplasms in the biliary tree.

The Visi-Pro is made from a 316L stainless steel tube with a diameter of 0.9 mm cut into an open lattice design; tantalum radiopaque markers are placed at the proximal and distal ends of the stent for guided placement. For delivery, the stent is mounted onto a tightly-folded balloon catheter, and then expanded and deployed by inflating the balloon. Other features include solid radial strength, flexibility, superior trackability, and a unique 5-fold balloon wrap that improves retraction.

In a prospective, multicenter, nonrandomized study that enrolled 75 patients at 17 centers in the United States and Europe, The Visi-Pro met its primary nine month endpoint, with a major adverse event rate of just 4%. Additionally, the technology achieved 100% device success, with primary patency and freedom from clinically-driven target lesion revascularization at nine months at 95.8%. The Visi-Pro is a product of Covidien (Dublin, Ireland), and has received the European Community CE marking of approval.

“The nine month results were positive, demonstrating the effectiveness of the technology in treating patients with iliac disease, regardless of gender, lesion location, or severity,” said lead author John Rundback, MD, of the Holy Name Medical Center (Teaneck, NJ, USA). “A unique benefit of the Visi-Pro stent is its excellent visibility during deployment, which optimizes precise positioning and minimizes the risk of geographic miss that is inherent to iliac stent procedures.”

Related Links:

Covidien
Holy Name Medical



Channels

Critical Care

view channel

Transfusion Approach Reduces Death from Blood Loss

A new study shows that a blood transfusion with equal ratios of plasma, platelets, and red blood cells (RBCs) give patients a significantly better chance of survival. Researchers at the University of Maryland (College Park, USA), the University of Texas Health Science Center (Houston, USA), and other institutions conducted... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: Remote Intelligent Telehealth Assistant (RITA) (Photo courtesy of PR Newswire).

Telehealth Robot Launched to Increase Productivity of Doctors in Clinics and Hospitals

A robot uses high-definition monitors, high-speed components, and wireless communications, and serves as a telehealth media center to give doctors more flexibility in treating and assisting patients remotely.... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.